Shares of Ziopharm Oncology Inc. (NASDAQ:ZIOP) were down 3.6% on Thursday . The company traded as low as $4.80 and last traded at $4.84, with a volume of 751,125 shares. The stock had previously closed at $5.02.

A number of analysts recently weighed in on ZIOP shares. Vetr lowered shares of Ziopharm Oncology from a “strong-buy” rating to a “buy” rating and set a $9.76 target price on the stock. in a report on Monday, April 18th. Mizuho upped their target price on shares of Ziopharm Oncology from $6.00 to $7.00 and gave the stock a “neutral” rating in a report on Wednesday, May 11th. Zacks Investment Research raised shares of Ziopharm Oncology from a “sell” rating to a “hold” rating in a report on Wednesday, May 11th. Wells Fargo & Co. reissued a “sell” rating and issued a $6.50 price target on shares of Ziopharm Oncology in a research note on Thursday, May 12th. Finally, Griffin Securities reissued a “buy” rating and issued a $21.00 price target on shares of Ziopharm Oncology in a research note on Thursday, May 26th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. Ziopharm Oncology has a consensus rating of “Hold” and a consensus price target of $9.55.

The firm’s market capitalization is $632.85 million. The stock’s 50 day moving average price is $5.55 and its 200 day moving average price is $6.78.

Ziopharm Oncology (NASDAQ:ZIOP) last posted its quarterly earnings data on Tuesday, May 10th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by $0.01. During the same quarter last year, the firm posted ($0.69) earnings per share. The company had revenue of $1.97 million for the quarter, compared to the consensus estimate of $1.89 million. The company’s revenue was up 623.9% compared to the same quarter last year. Equities analysts forecast that Ziopharm Oncology Inc. will post ($0.42) earnings per share for the current fiscal year.

Several institutional investors have bought and sold shares of the company. California Public Employees Retirement System increased its position in Ziopharm Oncology by 567.2% in the fourth quarter. California Public Employees Retirement System now owns 307,366 shares of the biotechnology company’s stock worth $2,554,000 after buying an additional 261,300 shares during the last quarter. Morgan Stanley increased its position in Ziopharm Oncology by 5.1% in the fourth quarter. Morgan Stanley now owns 1,618,205 shares of the biotechnology company’s stock worth $13,447,000 after buying an additional 78,583 shares during the last quarter. Swiss National Bank increased its position in Ziopharm Oncology by 2.2% in the fourth quarter. Swiss National Bank now owns 159,220 shares of the biotechnology company’s stock worth $1,323,000 after buying an additional 3,500 shares during the last quarter. Finally, California State Teachers Retirement System increased its position in Ziopharm Oncology by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 212,521 shares of the biotechnology company’s stock worth $1,766,000 after buying an additional 3,354 shares during the last quarter.

ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.